HKEX's Liu Ying: 19 companies have dual-listed in A+H shares in the first five months, exceeding the total number from last year.

Li Ying, Managing Director of the Hong Kong Stock Exchange and Co-chair of the Public Offerings Review Committee, stated at the HKEX Fintech Summit that the number of A+H listings has significantly increased since last year, with 19 listings in the first 5 months of this year, surpassing the total for last year. Li mentioned that HKEX introduced a consultation on the competitiveness of listing mechanisms earlier this year, including a review of the Weighted Voting Rights (WVR) system, and aims to publish a consultation summary this year. The responses received so far have been very positive. Li pointed out that 17 unprofitable biotech companies listed under Chapter 18A last year, and 6 have already done so this year. Since the introduction of Chapter 18A in 2018, a total of 90 companies have successfully listed, making Hong Kong a recognized center for biotech company listings. This also encourages companies in the medical and pharmaceutical sectors to consider listing in Hong Kong. As of the end of May, 18 technology companies have listed under Chapter 18C, raising a total of 35.1 billion yuan.